IZP completes Phase II asthma enrollment

Inflazyme (TSE:IZP) completed enrollment in a double-blind, placebo-controlled Phase II Allergen Challenge Trial of its IPL576,092 to treat asthma. The trial will use 2 dose levels of IPL576,092 to as...